These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

206 related items for PubMed ID: 24460259

  • 1. Clinical impact of palliative treatment using octreotide for inoperable malignant bowel obstruction caused by advanced urological cancer.
    Kubota H, Taguchi K, Kobayashi D, Naruyama H, Hirose M, Fukuta K, Kubota Y, Yasui T, Yamada Y, Kohri K.
    Asian Pac J Cancer Prev; 2013; 14(12):7107-10. PubMed ID: 24460259
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. A prospective study on the efficacy of octreotide in the management of malignant bowel obstruction in gynecologic cancer.
    Watari H, Hosaka M, Wakui Y, Nomura E, Hareyama H, Tanuma F, Hattori R, Azuma M, Kato H, Takeda N, Ariga S, Sakuragi N.
    Int J Gynecol Cancer; 2012 May; 22(4):692-6. PubMed ID: 22343971
    [Abstract] [Full Text] [Related]

  • 4. Octreotide for malignant bowel obstruction: twenty years after.
    Mercadante S, Porzio G.
    Crit Rev Oncol Hematol; 2012 Sep; 83(3):388-92. PubMed ID: 22277783
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Randomized clinical trial comparing octreotide and scopolamine butylbromide in symptom control of patients with inoperable bowel obstruction due to advanced ovarian cancer.
    Peng X, Wang P, Li S, Zhang G, Hu S.
    World J Surg Oncol; 2015 Feb 15; 13():50. PubMed ID: 25889313
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. [A clinical study using octreotide in relieving gastrointestinal symptoms due to bowel obstruction in a terminally ill cancer patient].
    Shima Y, Yamaguchi K, Miyata Y, Hyodo I, Yagi Y, Honke Y.
    Gan To Kagaku Ryoho; 2004 Sep 15; 31(9):1377-82. PubMed ID: 15446560
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Octreotide for long-lasting malignant bowel obstruction: two case reports.
    Mercadante S, Tartaglia L.
    Ann Palliat Med; 2024 Jan 15; 13(1):183-186. PubMed ID: 38316401
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [Pharmacological treatment of malignant bowel obstruction in severely ill and dying patients : a systematic literature review].
    Klein C, Stiel S, Bükki J, Ostgathe C.
    Schmerz; 2012 Sep 15; 26(5):587-99. PubMed ID: 23052994
    [Abstract] [Full Text] [Related]

  • 18. Radiological imaging change in a malignant bowel obstruction patient treated with octreotide.
    Shinjo T, Kagami R.
    Support Care Cancer; 2009 Jun 15; 17(6):753-5. PubMed ID: 19277723
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Medical management of malignant bowel obstruction in patients with advanced cancer: 2021 MASCC guideline update.
    Davis M, Hui D, Davies A, Ripamonti C, Capela A, DeFeo G, Del Fabbro E, Bruera E.
    Support Care Cancer; 2021 Dec 15; 29(12):8089-8096. PubMed ID: 34390398
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.